Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending December 13, 2016. The document serves as an announcement regarding a corporate governance decision rather than a financial results report.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on the appointment of a new external auditor.
Material Changes
The primary material change disclosed is the intention to replace the current auditor, PricewaterhouseCoopers LLP (PwC), with Deloitte LLP. This decision follows a competitive tender process overseen by the Audit & Risk Committee.
Outlook, Management Commentary, and Risks
- Auditor Transition: PwC will continue as auditor for the year ending December 31, 2017, subject to shareholder reappointment. Deloitte is intended to take over for the accounting year ending December 31, 2018.
- Shareholder Approval: The appointment of Deloitte will be recommended for approval at the 2018 Annual General Meeting.
- Management Commentary: Judy Lewent, Chairman of the Audit & Risk Committee, described the tender process as thorough, open, and transparent, and thanked PwC for their service since 2001.
- Risks: The filing includes a standard cautionary statement that forward-looking statements are subject to risks and uncertainties, referencing Item 3.D 'Risk factors' in the 2015 Annual Report on Form 20-F.
Investor Verification Checklist
- Confirm the formal appointment of Deloitte LLP at the 2018 Annual General Meeting.
- Verify the reappointment of PwC for the 2017 fiscal year at the 2017 Annual General Meeting.
- Review the 2015 Annual Report on Form 20-F for detailed risk factors referenced in the cautionary statement.